Palatin Technologies, Inc.

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized ... read more

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast ... read more

CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued ... read more

CRANBURY, N.J., March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued ... read more

CRANBURY, N.J., March 15, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 25(th) Annual ROTH Conference on Monday, March 18, 2013, at 1:00 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel ... read more

CRANBURY, N.J., March 4, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Cowen & Company 33(rd) Annual Health Care Conference on Tuesday, March 5, 2013, at 9:20 a.m. Eastern Time. The conference will be held at the ... read more

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012. Palatin ... read more

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by ... read more

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15(th) Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15(th) Annual BIO CEO & Investor Conference will take place February ... read more

CRANBURY, N.J., Jan. 3, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today it has received net proceeds of approximately $1.75 million of non-dilutive funding through the New Jersey Economic Development Authority's tax credit transfer program. Palatin Technologies sold both New Jersey net operating ... read more